A plant filing the same tablet in Europe and the US has to pick one PPQ batch count and defend it to two sets of inspectors.
EU GMP Annex 15, revised in 2015, treats three consecutive batches under routine conditions as a common minimum, with the number justified from risk. The FDA's 2011 process validation guidance never gives a figure. It splits the work into Stage 1 process design, Stage 2 process qualification and Stage 3 continued process verification, and asks whether the Stage 2 data show a capable process.
The count therefore stands or falls on the written rationale. Rationales that survive questioning usually start with commercial-scale history: how many batches exist and how far each critical quality attribute moved between them. Parameters running near the edge of their proven range add variation and push the number up. A platform process or a sister product on the same line earns some of it back. The better rationales finish with a statistical target, for example a capability index on the CQAs, and work out how many batches it takes to estimate that index with reasonable confidence. For a new sterile product with thin scale-up data, that arithmetic often lands above three.
PPQ comes after the facility's own IQ and OQ, the earlier stretch of the V-model where our commissioning and qualification work sits.
Industries




